on all orders above $300.00

FREE Pills!

via4gra pills

for free with every order



Less than in your
local pharmacy

Search by letter:

Gyrablock (Noroxin)

Rating of sales:          


Gyrablock is in a group of antibiotics called fluoroquinolones (flor-o-KWIN-o-lones). Gyrablock fights bacteria in the body. Gyrablock is used to treat bacterial infections of the prostate and urinary tract. Gyrablock also treats gonorrhea. Gyrablock may also be used for purposes not listed in this medication guide.

Other names for this medication:
Ambigram, Danilon, Loxone, Nolicin, Norbactin, Norflohexal, Norfloxacin, Norilet, Normax, Noroxin, Noroxine, Oranor, Uroflox, Uroxacin

Similar Products:
Cipro, Levaquin, Quixin, Tequin, Avelox, Ocuflox


Also known as:  Noroxin.


Gyrablock comes as a tablet to take by mouth. It is usually taken twice a day for 3 to 28 days. The length of treatment depends on the type of infection being treated. Your doctor will tell you how long to take Gyrablock. Take Gyrablock at around the same times every day and try to space your doses 12 hours apart. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take Gyrablock exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Take Gyrablock at least 1 hour before or 2 hours after meals or after drinking milk or eating dairy products.

Swallow the tablets with a full glass of water.

You should begin to feel better during the first few days of your treatment with Gyrablock. If your symptoms do not improve or if they get worse, call your doctor.

Take Gyrablock until you finish the prescription, even if you feel better. Do not stop taking Gyrablock without talking to your doctor unless you experience certain serious side effects listed in the IMPORTANT WARNING or SIDE EFFECT sections. If you stop taking Gyrablock too soon or if you skip doses, your infection may not be completely treated and the bacteria may become resistant to antibiotics.

Gyrablock is also sometimes used to treat certain infections of the stomach and intestines. Talk to your doctor about the risks of using this medication for your condition.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.


Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.

Take Gyrablock with a full glass of water (8 ounces). Drink several extra glasses of fluid each day to prevent crystals from forming in the urine.

Take Gyrablock on an empty stomach 1 hour before or 2 hours after eating a meal, drinking milk, or eating a dairy product such as yogurt or cheese.

If you are being treated for gonorrhea, your doctor may also have you tested for syphilis, another sexually transmitted disease.

Take this medication for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Skipping doses may also increase your risk of further infection that is resistant to antibiotics. Gyrablock will not treat a viral infection such as the common cold or flu.


If you overdose Generic Gyrablock and you don't feel good you should visit your doctor or health care provider immediately.


Store at room temperature between 15 and 30 degrees C (59 and 86 degrees F) away from moisture and heat. Keep bottle closed tightly. Throw away any unused medicine after the expiration date. Keep out of the reach of children.

Side effects

The most common side effects associated with Gyrablock are:

  • thuoc gyrablock 400 mg
  • gyrablock medicine
  • gyrablock tablets
  • gyrablock 400 mg alkohol
  • gyrablock 400 mg cena
  • gyrablock 400 tablets
  • gyrablock 400 mg
  • gyrablock 400 mg dosage
  • gyrablock and alcohol
  • gyrablock pills
  • gyrablock 400 mg norfloxacin alcohol
  • gyrablock drug
  • gyrablock dosage
  • liek gyrablock 400 mg
  • gyrablock antibiotic
  • gyrablock 400 mg norfloxacin

Side effect occurrence does not only depend on medication you are taking, but also on your overall health and other factors.


Taking norfloxacin increases the risk that you will develop tendinitis (swelling of a fibrous tissue that connects a bone to a muscle) or have a tendon rupture (tearing of a fibrous tissue that connects a bone to a muscle) during your treatment or for up to several months afterward. These problems may affect tendons in your shoulder, your hand, the back of your ankle, or in other parts of your body. Tendinitis or tendon rupture may happen to people of any age, but the risk is highest in people over 60 years of age. Tell your doctor if you have or have ever had a kidney, heart, or lung transplant; kidney disease; a joint or tendon disorder such as rheumatoid arthritis (a condition in which the body attacks its own joints, causing pain, swelling, and loss of function); or if you participate in regular physical activity. Also tell your doctor if you have ever had any tendon problems during or after your treatment with norfloxacin or another quinolone or fluoroquinolone antibiotic. Tell your doctor and pharmacist if you are taking oral or injectable steroids such as dexamethasone (Decadron, Dexpak), methylprednisolone (Medrol), or prednisone (Sterapred). If you experience any of the following symptoms of tendinitis, stop taking norfloxacin, rest, and call your doctor immediately: pain, swelling, tenderness, stiffness, or difficulty in moving a muscle. If you experience any of the following symptoms of tendon rupture, stop taking norfloxacin and get emergency medical treatment: hearing or feeling a snap or pop in a tendon area, bruising after an injury to a tendon area, or inability to move or bear weight on an affected area.

Taking norfloxacin may worsen muscle weakness in people with myasthenia gravis (a disorder of the nervous system that causes muscle weakness) and cause severe difficulty breathing or death. Tell your doctor if you have myasthenia gravis. Your doctor may tell you not to take norfloxacin. If you have myasthenia gravis and your doctor tells you that you should take norfloxacin, call your doctor immediately if you experience muscle weakness or difficulty breathing during your treatment.

Talk to your doctor about the risks of taking norfloxacin.

gyrablock pills

The susceptibility of 11 clinical isolates of Mycobacterium tuberculosis, 3 M. kansasii, 3 M. xenopi, 2 M. scrofulaceum, 2 M. marinum, 2 M. malmoense to fleroxacin, ciprofloxacin, norfloxacin, rifampicin, isoniazid, ethambutol, and streptomycin was determined by the standard proportion method (Middlebrook 7H10 agar). All M. tuberculosis, M. kansasii, M. xenopi, M. scrofulaceum, M. marinum, and M, malmoense isolates including those resistant to conventional antimycobacterials were inhibited by 0.5 mg/l of fleroxacin and ciprofloxacin, the lowest tested concentration. Fleroxacin and ciprofloxacin along with ofloxacin, pefloxacin, ansamycin, clofazimine and cycloserine were also tested against 14 isolates of the M. avium complex. Nine of 14 strains (64%) of the M. avium complex were found susceptible to 4 mg/l of fleroxacin and a similar percentage to the other quinolones. On the basis of its in-vitro potency and its favourable pharmacokinetic properties fleroxacin appears to be sufficiently active to warrant further experimental trials against difficult to treat mycobacteria.

gyrablock medicine

Lomefloxacin (NY-198), a new antimicrobial quinolone, was examined for its antimicrobial activities against clinical isolates and clinical efficacies to biliary tract infections. The following results were obtained. 1. The MICs of NY-198 against Escherichia coli (20 strains) and Klebsiella pneumoniae (20 strains) were good and similar to those of ofloxacin (OFLX) or norfloxacin (NFLX). The MICs of NY-198 against Pseudomonas aeruginosa (20 strains) were inferior by 1 dilution factor to OFLX or NFLX, and against Enterococcus faecalis (10 strains), they were similar to NFLX and slightly inferior to OFLX. 2. NY-198 was administered to 8 patients with biliary tract infections (acute cholecystitis 7 cases, chronic cholangitis 1 case). The results were good in 7 and unevaluable in 1 case because the duration of the therapy was too short. 3. As for side effects, mild urticaria was observed in 1 case and epigastralgia with nausea in another. As for abnormal laboratory test values slight elevations of GOT and GPT were recognized in 1 case. 4. In conclusion, we consider NY-198 is a useful oral drug for the treatment of biliary tract infections.

gyrablock 400 mg norfloxacin alcohol

Enteropathogenic Escherichia coli(EPEC) is a major cause of diarrhoea in children below 5 years of age. Serotyping is classical method for identification of EPEC strains. But serotypic markers are rarely sufficient to reliably identify the strains as Escherichia coli. Introduction of PCR methodology which depends on detection of virulence factors has provided a practical and rapid way of detecting diarrhoeagenic Esch.coli. Multiantibiotic resistant EPEC strains are a common phenomenon with world wide extension. Moreover for the selection of appropriate therapy of dirrhoeas, knowledge of local antimicrobial therapy pattern plays an important role.

gyrablock 400 tablets

An open randomised controlled clinical trial with 160 adults with acute watery diarrhoea and severe dehydration compared the efficacy of varying regimens of norfloxacin and doxycycline for the treatment of cholera caused by Vibrio cholerae 0139 Bengal. Data were analysed for the 111 patients who were faeces culture positive for V. cholerae 0139. In addition to rehydration therapy, 28 patients received 300 mg of doxycycline as a single dose on admission, 26 patients received norfloxacin 400 mg bd for three days, 28 patients received a single dose of 800 mg of norfloxacin and 29 patients received no antibiotic (control group). Patients in the three treatment groups and control group had comparable characteristics on admission. All three treatment groups had reduced stool output, duration of diarrhoea and fluid intake compared with the control group. Multidose norfloxacin treatment significantly reduced stool output, duration of diarrhoea and fluid requirement compared with the other regimens.

gyrablock drug

This study was performed to determine the prevalence of toxigenic C. difficile in beef and mutton meats consumed as human food in Isfahan, central part of Iran. Furthermore the polymerase chain reaction (PCR)-ribotyping employed to compare the genetic pattern of positive isolates in meat with clinical ones.

gyrablock 400 mg norfloxacin

A novel series of quinolone triazoles were synthesized and characterized by IR, NMR, MS and HRMS spectra. All the newly prepared compounds were screened for their antimicrobial activities against seven bacteria and four fungi. Bioactive assay manifested that most of new compounds exhibited good or even stronger antibacterial and antifungal activities against the tested strains including multi-drug resistant MRSA in comparison with reference drugs Norfloxacin, Chloromycin and Fluconazole. The preliminary interactive investigations of compound 6b with calf thymus DNA by fluorescence and UV-vis spectroscopic methods revealed that compound 6b could effectively intercalate DNA to form compound 6b-DNA complex which might block DNA replication and thus exert its antimicrobial activities.

gyrablock 400 mg dosage

This study was conducted to examine a current baseline profile of antimicrobial resistance and virulence of Escherichia coli isolated from foods commonly sold in the market place in Vietnam. E. coli were isolated from 180 samples of raw meat, poultry and shellfish and also isolated from 43 chicken faeces samples. Ninety-nine E. coli isolates recovered from all sources were selected for the investigation of their susceptibility to 15 antimicrobial agents by the disk diffusion method. Eighty-four percent of the isolates were resistant to one or more antibiotics, and multi-resistance, defined as resistance to at least 3 different classes of antibiotics, was detected in all sources. The rates of multi-resistance were up to 89.5% in chicken, 95% in chicken faeces and 75% in pork isolates. Resistance was most frequently observed to tetracycline (77.8%), sulfafurazole (60.6%), ampicillin (50.5%), amoxicillin (50.5%), trimethoprim (51.5%), chloramphenicol (43.4%), streptomycin (39.4%), nalidixic acid (34.3%) and gentamicin (24.2%). In addition, the isolates also displayed resistance to fluoroquinolones (ciprofloxacin 16.2%, norfloxacin 17.2%, and enrofloxacin 21.2%), with chicken isolates showing the highest rates of resistance to these antibiotics (52.6-63.2%). Thirty-eight multi-resistant isolates were selected for further the examination of antibiotic resistance genes and were also evaluated for virulence gene profiles by multiplex and uniplex polymerase chain reaction. The beta-lactam TEM gene and tetracycline resistance tetA, tetB genes were frequently detected in the tested isolates (84.2% and 89.5% respectively). Genes which are responsible for resistance to streptomycin (aadA) (68.4%), chloramphenicol (cmlA) (42.1%), sulfonamides (sulI) (39.5%), trimethoprim (dhfrV) (26.3%) and kanamycin (aphA-1) (23.7%) were also widely distributed. Plasmid-mediated ampC genes were detected in E. coli isolates from chicken and pork. The isolates were tested for the presence of 58 virulence genes for adhesins, toxins, capsule synthesis, siderophores, invasins and others from different E. coli pathotypes. All of the tested isolates contained at least one virulence gene and there were 16 genes detected. Virulence genes detected were fimH (92.1%), bmaE (84.2%), TSPE4.C2 (42.1%), aidA AIDA-I (orfB) (31.6%), east1 (26.3%), traT (23.7%), and others including fyuA, iutA, chuA, yjaA, iss, iroN(E. coli), ibeA, aah (orfA), iha and papG allele III (10.5-2.6%). Typical toxin genes produced by enterohemorrhagic and enterotoxigenic E. coli pathotypes (a heat-stable toxin (ST), heat-labile toxin (LT) and Shiga toxin stx1, stx2) were not detected in any of these 38 isolates. The study has revealed that E. coli in raw foods is a significant reservoir of resistance and virulence genes.

gyrablock dosage

In vitro activity of four fluorinated quinolones: pefloxacin, norfloxacin, ciprofloxacin, ofloxacin were determined against various clinical isolates of mycobacteria. The method of agar dilution was used, seventy strains of ten species were tested: Mycobacterium tuberculosis (25), Mycobacterium bovis (5), Mycobacterium africanum (2), BCG (5), Mycobacterium kansasii (6), Mycobacterium marinum (5), Mycobacterium avium (11), Mycobacterium xenopi (6), Mycobacterium chelonae (3), Mycobacterium fortuitum (2). Except for Mycobacterium avium and Mycobacterium chelonae (CMI 100% greater than 8 mg/l) fluorinated quinolones showed activity against tested mycobacteria (CMI 100% less than or equal to 8 mg/l). Ofloxacin and ciprofloxacin where found to be the most active. Their activity against the different strains of Mycobacterium tuberculosis was unrelated to their susceptibility or resistance to the antituberculous drugs.

Target Point Shipping Method Tracking Delivery Time Price
Worldwide shipping

Worldwide shipping

Registered Mail  Not trackable 14-21 business days USD 20.00 per order
EMS  Trackable, where available 5-9 business days USD 30.00 per order

Delivery time is:

Registered Mail - 14-21 business days, prices - USD 20.00, no signature is required on delivery.
EMS - 5-9 business days, prices - USD 30.00, signature is required on delivery.
Your order will be packed safe and secure and dispatched within 24 hours.

front back side

This is exactly how your parcel will look like (pictures of a real shipping item). It has a look of a regular private letter and does not disclose its contents. Size - 9.4x4.3x0.3 inches (24x11x0.7cm).

 Show Hide 
gyrablock 400 mg norfloxacin 2015-05-29

Norfloxacin is a very potent drug. Adsorption of this drug may account for a significant fraction of total dose, hence the adsorption effect is of great significance. In the present investigation adsorption interaction study various adsorbents, was undertaken using, viz., activated charcoal, bentonite, kaolin, potato Clamoxin Pediatrico 125 Mg starch, talc and lactose by permeation technique. It was observed that forces through which the adsorption interaction is mediated are important to the effect obtained in vitro and that with further knowledge it may be possible to predict in vivo effect from the results of in vitro findings.

gyrablock dosage 2016-03-05

Mean initial norfloxacin uptake in the four resistant strains (104 ng/mg of dry cells) was significantly lower than that in the seven sensitive strains (158 ng/mg of dry cells) (p < 0.05). The mean uptake after 20 minutes was also significantly lower in the four resistant strains ( Omnicef Capsule 130 ng/mg of dry cells) than in the seven sensitive strains (194 ng/mg of dry cells) (p < 0.05). However, there was no significant difference in mean norfloxacin accumulation after 20 minutes between the four resistant strains (26 ng/mg of dry cells) and the seven sensitive strains (36 ng/mg of dry cells). The accumulation of norfloxacin after 20 minutes was almost zero in two of the four resistant strains, while the remaining two strains accumulated norfloxacin as well as the sensitive strains.

liek gyrablock 400 mg 2016-06-30

This work studied the sustained release of ciprofloxacin or norfloxacin and gentamicin from nonstoichiometric hydroxyapatite (nHA) and anionic collagen composite. Within the first 24 and 48 h, the total antibiotic supply was significantly higher than the minimal inhibitory concentration required for the majority of the gram-negative bacteria. Although gentamicin was completely released from Megamox Suspension 250 the matrix after 48 h by a normal diffusion mechanism, ciprofloxacin or norfloxacin release was characterized by a 2-phase release mechanism due to binding to nHA by complexation with calcium ion. Under the conditions studied, most of the norfloxacin or ciprofloxacin only will be disposable due to bioresorption or dissociation of the complexes. In conclusion, due to its biocompatibility nHA-anionic collagen composite may be a convenient support for the double sustained release of the antibiotics gentamicin and ciprofloxacin/norfloxacin for the control of bone infection while promoting bone tissue growth.

gyrablock 400 mg norfloxacin alcohol 2016-01-19

To investigate the antimicrobial resistance status and pulsed field gel Cefspan 200 Mg Untuk Apa electrophoresis (PFGE) patterns of Salmonella Enteritidis (S.Enteritidis) strains in Henan province.

gyrablock pills 2017-11-28

Among older patients receiving spironolactone, treatment with trimethoprim-sulfamethoxazole was associated with a major increase in the risk of admission to hospital for hyperkalaemia. This drug combination should be avoided when Antirobe Tablets possible.

gyrablock antibiotic 2015-04-24

We have undertaken the inventory of Clavaseptin 250 Mg Tablets the drug transporters subfamily, included in the major facilitator superfamily (MFS), encoded by the complete genome of Mycobacterium tuberculosis (MTB). These proteins were identified on the basis of their characteristic stretches of amino acids and transmembrane segments (TMS) number.

gyrablock and alcohol 2015-10-20

Recently, we reported that ciprofloxacin, an antimicrobial agent with gamma-aminobutyric acid (GABA(A)) receptor antagonist properties, significantly increases hepatic regenerative activity in animal models of alcohol-induced liver disease and cirrhosis. In the present study, we documented the effects of ciprofloxacin on survival and hepatic regeneration in a D-galactosamine (D-gal)-induced model of acute hepatic injury in rats. One hundred nineteen adult, male Sprague-Dawley rats (n = 19-20/group) were treated with intraperitoneal D-gal (total dose: 2.5 g/kg), followed by gastric gavage with either saline, ciprofloxacin (10, 50, or 100 mg/kg), norfloxacin (250 mg/kg), or intraperitoneal putrescine (300 micromol/kg), a potent hepatic growth promoter. Mortality rates were then documented over a 4-day period. An additional 45 rats (n = 15/group) received a sublethal dose of D-gal (1.0 g/kg), followed by gastric gavage with either saline or Novax 100 Mg ciprofloxacin (100 mg/kg), or intraperitoneal putrescine (300 micromol/kg). In these rats, hepatic regenerative activity was documented at 12, 24, and 60 hours post-D-gal by 3H-thymidine incorporation into hepatic DNA and proliferating cell nuclear antigen (PCNA) staining. In the survival study, a dose-response effect of ciprofloxacin on survival was observed (ciprofloxacin: 10 mg/kg, 10%; 50 mg/kg, 26%; and 100 mg/kg, 35%) with the results in the 100-mg/kg-treated group being significant when compared with the 5% survival rate in saline-treated controls (P < .05). Survival figures in the norfloxacin- and putrescine-treated groups were not significantly improved (15% and 25%, respectively). In the regeneration study, compared with the D-gal + saline-treated control group, DNA synthesis rates at 60 hours were increased in the D-gal + ciprofloxacin and D-gal + putrescine groups (10.2 +/- 3.3 vs. 18.2 +/- 5.1 and 18.8 +/- 6.8 x 10(3) dpm/mg DNA respectively; P < .05). The results of PCNA staining also supported enhanced hepatic regeneration in the ciprofloxacin-treated group at 60 hours (saline, 13.4 +/- 3.7; ciprofloxacin, 47.4 +/- 7.3; and putrescine, 8.4% +/- 2.8% hepatocytes staining positive). Ciprofloxacin at a dose of 100 mg/kg significantly improves survival and hepatic regenerative activity in this animal model of acute hepatic injury.